Shots:
- The P-III GEMINI 1 study involves assessing AGN-190584 (pilocarpine 1.25%, qd) ophthalmic solution in 323 patients in a ratio (1:1) with presbyopia for 30days.
- The study demonstrated that AGN-190584 met both its 1EPs & 2EPs with patients achieving near & intermediate vision gains. In addition, AGN-190584 showed no loss of distance vision, rapid onset of action and sustained vision gains of up to 6hrs.
- PRO data showed improvement in ability and satisfaction in near vision reading as well as a reduction in the use of presbyopia coping mechanisms during the last 7days of the trial. If approved, AGN-190584 is expected to be the first eye drop for presbyopia
Click here to read the full press release/ article | Ref: PRNewswire | Image: StraitTimes
The post AbbVie Presents Results of AGN-190584 in P-III GEMINI 1 Study for Presbyopia at 2021 ASCRS first appeared on PharmaShots.
